Motion Sickness
📧 Sign up to get email alerts when something new happens for Motion Sickness.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness [Phase 3]
Phase 3 open-label trial update on the safety and efficacy of Tradipitant for motion sickness; the study is currently active, not recruiting…
-
CLINICAL_TRIALS research · 2026-03-25Clinical Trial Update: Virtual Reality Sickness Questionnaire: Psychometrics in Stroke Patients
This trial update describes a study evaluating the psychometric properties of the Virtual Reality Sickness Questionnaire in stroke patients,…
-
FDA approval · 2026-02-09FDA Approved: SCOPOLAMINE TRANSDERMAL SYSTEM — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
The FDA approved a supplemental application for Scopolamine Transdermal System from Padagis Israel Pharmaceuticals Ltd.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Three-Axis Wearable Adaptive Vestibular Stimulator [NA]
A Mayo Clinic-sponsored trial is evaluating a three-axis wearable adaptive vestibular stimulator for motion sickness; the study is currently…
-
CLINICAL_TRIALS trial_result · 2026-01-05Clinical Trial Update: Virtual Reality in the Rehabilitation of Visually Induced Motion Sickness [NA]
A clinical trial investigating virtual reality rehabilitation for visually induced motion sickness has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-29Clinical Trial Update: The Minimum Effective Dose (ED90) of Liposomal Bupivacaine for Preserving Motor Function [Phase 4]
Phase 4 trial evaluating the minimum effective dose (ED90) of liposomal bupivacaine for preserving motor function in motion sickness has bee…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: StableEyes With Active Neurofeedback [NA]
A Johns Hopkins University study titled StableEyes With Active Neurofeedback is currently recruiting for vestibular disorders, including ves…
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: Nebulizer Delivery of Intranasal Scopolamine [Phase 1]
This update reports the completion of a Phase 1 trial evaluating nebulized intranasal scopolamine for motion sickness.
-
FDA approval · 2025-08-22FDA Approved: DIPHENHYDRAMINE HYDROCHLORIDE — Original Application (Micro Labs Limited)
FDA approved a Diphenhydramine hydrochloride product from Micro Labs Limited under Original Application (ANDA 219845). This approval covers …
-
FDA approval · 2025-08-20FDA Approved: SCOPOLAMINE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for scopolamine filed by Zydus Pharmaceuticals USA Inc., indicating an update to an existing AND…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation [NA]
A clinical trial is evaluating a device to reduce motion sickness and spatial disorientation; the study is currently recruiting.
-
FDA approval · 2025-06-24FDA Approved: PROMETHAZINE HYDROCHLORIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for promethazine hydrochloride from Hikma Pharmaceuticals USA, confirming the approval of a generic …
-
FDA approval · 2025-06-10FDA Approved: TRANSDERM SCOP — Supplemental Application (Baxter Healthcare Corporation)
The FDA approved a supplemental application for TRANSDERM SCOP (scopolamine) from Baxter Healthcare Corporation.
-
FDA approval · 2025-06-09FDA Approved: SCOPOLAMINE — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved a generic scopolamine product from Amneal Pharmaceuticals NY LLC under an original ANDA (ANDA218384).
-
CLINICAL_TRIALS trial_result · 2025-06-03Clinical Trial Update: Impact of Different Types of Virtual Reality Games on Motion Sickness and Ocular in Adults: A Pilot Study [NA]
A completed pilot clinical trial from He Eye Hospital evaluated how different types of virtual reality games influence motion sickness and o…
-
CLINICAL_TRIALS trial_result · 2025-05-09Clinical Trial Update: Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness [Phase 2]
Phase 2 trial of tradipitant for motion sickness has completed with results posted.
-
CLINICAL_TRIALS withdrawal · 2025-04-16Clinical Trial Update: Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma [NA]
A clinical trial (NCT04196933) evaluating vestibular compensation after intervention for vestibular schwannoma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-04-04Clinical Trial Update: Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness [Phase 3]
A Phase 3 study evaluating tradipitant for motion sickness has completed, and results were posted in 2025.
-
FDA approval · 2025-01-22FDA Approved: PROCHLORPERAZINE EDISYLATE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for Prochlorperazine edisylate from Eugia US LLC. The approval pertains to a supplemental submission…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness [Phase 3]
Phase 3 trial evaluating Tradipitant for motion sickness has completed and results have been posted.
-
CLINICAL_TRIALS research · 2024-10-26Clinical Trial Update: Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
This completed cross-sectional study evaluated vestibulo-ocular reflex function in individuals with chronic motion sensitivity (motion sickn…
-
CLINICAL_TRIALS trial_result · 2024-07-25Clinical Trial Update: The Effect of Training Given to With Hypertension [NA]
This clinical trial update notes the completion of a training intervention study in individuals with hypertension, with motion sickness list…
-
CLINICAL_TRIALS research · 2024-05-17Clinical Trial Update: Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance [Phase 2]
Phase 2 clinical trial evaluating intranasal scopolamine combined with sensory augmentation to mitigate motion sickness and enhance sensorim…
-
CLINICAL_TRIALS research · 2024-05-16Clinical Trial Update: Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance [Phase 2]
Phase 2 clinical trial evaluating intranasal scopolamine combined with sensory augmentation to mitigate motion sickness during spaceflight-r…
-
FDA approval · 2024-05-06FDA Approved: SCOPOLAMINE — Original Application (Rhodes Pharmaceuticals L.P.)
FDA approved Rhodes Pharmaceuticals L.P.'s original application for scopolamine (generic), enabling marketing of a scopolamine product.